Clinical Research Directory
Browse clinical research sites, groups, and studies.
Replication of the Heads Up Atopic Dermatitis Trial With Registry Data
Sponsor: Technische Universität Dresden
Summary
The goal is the replication of the primary outcome (EASI 75 at week 16) of the Heads Up trial (Blauvelt, A, Teixeira, H, Simpson, E et al (2021) doi:10.1001/jamadermatol.2021.3023) and the evaluation of the patient reported outcomes (POEM, DLQI and RECAP) in a head-to-head comparison of upadacitinib versus dupilumab treatment in moderate-to-severe atopic dermatitis (AD).
Official title: Pragmatic Replication of the Heads Up Head-to-head Study of Upadacitinib and Dupilumab With TREATgermany Registry Data
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
240
Start Date
2021-08-02
Completion Date
2025-12-31
Last Updated
2025-08-21
Healthy Volunteers
No
Conditions
Interventions
Upadacitinib
30 mg tablet daily
Dupilumab
300 mg injection every other week
Locations (1)
Center for Evidence Based Health Care
Dresden, Saxony, Germany